BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 26077902)

  • 1. Hepatic Resection for Disappearing Liver Metastasis: a Cost-Utility Analysis.
    Spolverato G; Vitale A; Ejaz A; Cosgrove D; Cowzer D; Cillo U; Pawlik TM
    J Gastrointest Surg; 2015 Sep; 19(9):1668-75. PubMed ID: 26077902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver Resection for Advanced Intrahepatic Cholangiocarcinoma: A Cost-Utility Analysis.
    Cillo U; Spolverato G; Vitale A; Ejaz A; Lonardi S; Cosgrove D; Pawlik TM
    World J Surg; 2015 Oct; 39(10):2500-9. PubMed ID: 26148521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver Resection for Breast Cancer Liver Metastases: A Cost-utility Analysis.
    Spolverato G; Vitale A; Bagante F; Connolly R; Pawlik TM
    Ann Surg; 2017 Apr; 265(4):792-799. PubMed ID: 28266967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Net health benefit of hepatic resection versus intraarterial therapies for neuroendocrine liver metastases: A Markov decision model.
    Spolverato G; Vitale A; Ejaz A; Kim Y; Cosgrove D; Schlacter T; Geschwind JF; Pawlik TM
    Surgery; 2015 Aug; 158(2):339-48. PubMed ID: 25999251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and cost-effectiveness of peri-operative versus post-operative chemotherapy for resectable colorectal liver metastases.
    Ercolani G; Cucchetti A; Cescon M; Peri E; Brandi G; Del Gaudio M; Ravaioli M; Zanello M; Pinna AD
    Eur J Cancer; 2011 Oct; 47(15):2291-8. PubMed ID: 21652204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of hepatic metastasectomy in patients with metastatic colorectal carcinoma: a state-transition Monte Carlo decision analysis.
    Gazelle GS; Hunink MG; Kuntz KM; McMahon PM; Halpern EF; Beinfeld M; Lester JS; Tanabe KK; Weinstein MC
    Ann Surg; 2003 Apr; 237(4):544-55. PubMed ID: 12677152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metastatic colorectal carcinoma: cost-effectiveness of percutaneous radiofrequency ablation versus that of hepatic resection.
    Gazelle GS; McMahon PM; Beinfeld MT; Halpern EF; Weinstein MC
    Radiology; 2004 Dec; 233(3):729-39. PubMed ID: 15564408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete radiological response of colorectal liver metastases after chemotherapy: what can we expect?
    Gaujoux S; Goéré D; Dumont F; Souadka A; Dromain C; Ducreux M; Elias D
    Dig Surg; 2011; 28(2):114-20. PubMed ID: 21540596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effective imaging for resectability of liver lesions in colorectal cancer: an economic decision model.
    Saing S; Haywood P; Duncan JK; Ma N; Cameron AL; Goodall S
    ANZ J Surg; 2018 Jun; 88(6):E507-E511. PubMed ID: 28982209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical effectiveness and cost-effectiveness of ablative therapies in the management of liver metastases: systematic review and economic evaluation.
    Loveman E; Jones J; Clegg AJ; Picot J; Colquitt JL; Mendes D; Breen DJ; Moore E; George S; Poston G; Cunningham D; Ruers T; Primrose J
    Health Technol Assess; 2014 Jan; 18(7):vii-viii, 1-283. PubMed ID: 24484609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of liver transplantation in patients with colorectal metastases confined to the liver.
    Bjørnelv GMW; Dueland S; Line PD; Joranger P; Fretland ÅA; Edwin B; Sørbye H; Aas E
    Br J Surg; 2019 Jan; 106(1):132-141. PubMed ID: 30325494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy.
    Auer RC; White RR; Kemeny NE; Schwartz LH; Shia J; Blumgart LH; Dematteo RP; Fong Y; Jarnagin WR; D'Angelica MI
    Cancer; 2010 Mar; 116(6):1502-9. PubMed ID: 20120032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomised controlled trial to assess the cost-effectiveness of intensive versus no scheduled follow-up in patients who have undergone resection for colorectal cancer with curative intent.
    Mant D; Gray A; Pugh S; Campbell H; George S; Fuller A; Shinkins B; Corkhill A; Mellor J; Dixon E; Little L; Perera-Salazar R; Primrose J
    Health Technol Assess; 2017 May; 21(32):1-86. PubMed ID: 28641703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma.
    Cucchetti A; Piscaglia F; Cescon M; Colecchia A; Ercolani G; Bolondi L; Pinna AD
    J Hepatol; 2013 Aug; 59(2):300-7. PubMed ID: 23603669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is carcino-embryonic antigen useful in the follow-up management of patients with colorectal liver metastases?
    Bakalakos EA; Burak WE; Young DC; Martin EW
    Am J Surg; 1999 Jan; 177(1):2-6. PubMed ID: 10037299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging in disappearing colorectal liver metastases and their accuracy: a systematic review.
    Barimani D; Kauppila JH; Sturesson C; Sparrelid E
    World J Surg Oncol; 2020 Oct; 18(1):264. PubMed ID: 33032620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic resection vs minimally invasive radiofrequency ablation for the treatment of colorectal liver metastases: a Markov analysis.
    Khajanchee YS; Hammill CW; Cassera MA; Wolf RF; Hansen PD
    Arch Surg; 2011 Dec; 146(12):1416-23. PubMed ID: 22288086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disappearing liver metastases from colorectal cancer: impact of modern imaging modalities.
    Sturesson C; Nilsson J; Lindell G; Andersson RG; Keussen I
    HPB (Oxford); 2015 Nov; 17(11):983-7. PubMed ID: 26252426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performing Gadoxetic Acid-Enhanced MRI After CT for Guiding Curative Treatment of Early-Stage Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
    Suh CH; Kim KW; Park SH; Kim SY; Woo DC; Shin S; Pyo J; Shinagare AB; Ramaiya NH; Lim YS
    AJR Am J Roentgenol; 2018 Feb; 210(2):W63-W69. PubMed ID: 29091004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.